MGTX News & Events

MeiraGTx announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia. "Today we are very pleased to be releasing 3-year data from the Phase 1 AQUAx study which includes the full 36-month data from all cohorts," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. "The 3-year data shows remarkable maintenance of the unprecedented improvements seen in response to AAV-hAQP1 treatment at 12 months. XQ responses are maintained over 3 years as is unstimulated saliva flow - the objective measure of the therapy's mechanism of action. The durability we are seeing with AAV-hAQP1 is extraordinary, particularly following the simple one-time treatment. In addition to the durability of the population data over three years, the consistency of responses within individual patients is also encouraging. This three-year durability data is changing the way AAV-hAQP1 treatment is viewed by physicians, as it is now being regarded as a simple one-time treatment that has disease modifying impact on patients with this lifelong, severely debilitating condition that has no other treatments."

MeiraGTx (MGTX) announced that it has entered into an asset purchase agreement with Johnson & Johnson (JNJ) to acquire all interests in bota-vec for the treatment of X-linked Retinitis Pigmentosa, XLRP. "We are extremely pleased to have reacquired bota-vec for the treatment of XLRP," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. "This is a unique opportunity to gain an asset at this stage in development with data supporting a meaningful benefit in patients with no alternative treatment, many of whom are waiting for this life changing therapy and hoping for expeditious approval." MeiraGTx will pay J&J a $25 million upfront cash payment and a one-time regulatory and commercial milestone tied to U.S. approval and U.S. sales performance of bota-vec for the treatment of XLRP, as well as a high double-digit royalty on global net sales starting in mid-2029.